Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues
Royalty and licensing revenue	$ 3,746	$ 1,649
Treatment investment revenue	80	54
Grant and contract revenue	1,609	0
Total revenue	5,435	1,703
Operating expenses
General and administrative	3,696	2,965
Research and development	3,567	2,421
License fees	0	5,625
Total operating expenses	7,263	11,011
Loss from operations	(1,828)	(9,308)
Other income (expense)
Interest income, net	122	5
Loss on foreign exchange	(30)	(8)
Total other income (expense)	92	(3)
Loss before provision for income taxes	(1,736)	(9,311)
Provision for income taxes	0	33
Net loss	$ (1,736)	$ (9,344)
Net loss per share of common stock:
Basic and Diluted (in dollars per share)	$ (0.44)	$ (3.68)
Weighted average shares outstanding used to compute net loss per share:
Basic and Diluted (in shares)	3,909,702	2,542,084